Status:
UNKNOWN
A Phase II Study of AS1411 in Renal Cell Carcinoma
Lead Sponsor:
Antisoma Research
Conditions:
Metastatic Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The aim of this study is to evaluate the efficacy of AS1411 in patients with Metastatic Renal Cell Carcinoma
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed renal cell carcinoma containing predominant clear cell histology
- Failed or intolerant to 1 or more previous lines of treatments (which must include a Tyrosine Kinase Inhibitor)
Exclusion
- Collecting duct histology
- A history of bleeding disorders or currently taking oral vitamin K antagonise medication
- Unstable brain metastases
- History of prior or concomitant malignancy (except for curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix, or other cancer for which the patient has been disease free for 3 years)
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00740441
Start Date
August 1 2008
End Date
March 1 2010
Last Update
September 25 2009
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
City of Hope
Duarte, California, United States, 91010
2
University of California, Davis Cancer Center
Sacramento, California, United States, 95817
3
University of California San Francisco
San Francisco, California, United States, 94143
4
St Francis Hospital
Beech Grove, Indiana, United States, 46107